$ASPN

ASPEN AEROGELS INC (ASPN): Results of Operations and Financial Condition

ASPEN AEROGELS INC (ASPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent Business Highlights Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarter Q3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15

Original reporting
Published Aug 6, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ASPN
Neutral
medium confidence
Mentioned
$ASPN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASPNNeutralHigh
01

Why it matters

Traders can reprice the stock based on the combination of a weak YoY Q2 revenue and net loss, plus a materially improved Q3 adjusted EBITDA range, while monitoring execution risk from the East Providence incident and the Statesboro asset sale process.

02

Market read

Fresh Q3 guidance ranges and incident cost assumptions create a clear near-term catalyst for earnings-model updates and risk management.

03

What to watch

Insurance recovery is expected to be collected in Q3, but guidance explicitly excludes business interruption recoveries, leaving margin outcomes sensitive to claim timing and incident-related cost creep.

Relevance 7/10Novelty 9/10Timing: today’s SEC 8-K release with Q3 2026 guidance ranges

Background

This SEC 8-K (Item 2.02) includes Aspen’s Q2 2026 financial results and a press-release exhibit with operational updates and forward guidance.

Company-level read

Ticker impact

$ASPNNeutralMedium confidence
Context

Aspen reported Q2 2026 results and guided Q3 revenue $65M to $80M and adjusted EBITDA $7M to $15M, citing East Providence incident costs.

Expected impact

Near-term volatility likely around the Q3 outlook ranges and any market skepticism about insurance recovery timing and margin durability.

Evidence & confidence

The filing provides fresh, decision-relevant numbers (Q2 print plus explicit Q3 revenue, net loss, and adjusted EBITDA ranges) and ties them to a specific operational disruption with insurance claims not assumed in the guidance.

Market effects

EV thermal barrier demand and regulatory/incentive sensitivity are highlighted as a driver of segment revenue volatility.

East Providence, Rhode Island manufacturing disruption and restart execution are central to near-term supply and cost dynamics.

European Thermal Barrier momentum and OEM program ramp (including JLR architectures) support longer-cycle demand visibility.

Counterpoint

The raised European outlook and JLR PyroThin award may not offset North American regulatory uncertainty quickly enough to sustain the adjusted EBITDA ramp.

Key entities

  • Aspen Aerogels, Inc.

    Reports Q2 2026 results, provides Q3 2026 guidance, and discusses the East Providence incident and staged manufacturing restart.

  • Jaguar Land Rover

    Awarded Aspen’s PyroThin for two next-generation vehicle architectures with start of production expected in 2027.

  • East Providence incident (April 2026)

    Property damage and incident-related costs drive Q2 losses; company expects insurance receivable collection in Q3.

Related articles

$ASPNMed

Aspen Aerogels Q2 Earnings Call Highlights

Aspen Aerogels (ASPN) reported Q2 gross profit of $3.3M (7% margin) after $5.3M of incremental costs tied to an April explosion at its East Providence plant. Adjusted gross profit was $8.6M (17%). GAAP net loss was $23.3M. The company is restarting the plant and expects full capacity in 1H 2027, while raising 2026 European Thermal Barrier revenue outlook to $20M-$30M.

$ASPNMed

Beerenberg Prevails in Patent Case Against Aspen Aerogels

South Korea’s Patent Court invalidated three Aspen Aerogels patents covering improved hydrophobic aerogel material, according to the company’s press release. The ruling upheld the Intellectual Property Trial and Appeal Board’s view that the patents failed patentability requirements. Beerenberg, an insulation-products firm, said the decision removes uncertainty over infringement claims.

$EQIXMedAI 8/10

Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here

Equinix (EQIX) reported Q2 revenue of $2.63B, up 16% YoY, beating estimates. AFFO was $11.78/share, up 19% YoY. The company raised full-year guidance and unveiled a multi-year growth plan. EQIX stock has surged 34% over the past year and offers a 1.98% dividend yield. Analysts rate it a 'Strong Buy' with an average price target of $1,232.19.

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.